Cardinal Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardinal Health, Inc.
The company plans to make a new EUA request prior to filing a BLA, but does not yet have a specific timeline. Meanwhile, it has been preparing for the drug’s distribution as a COVID-19 treatment.
Predictions made by Kim Trautman, lead author of the US FDA’s Quality System Regulation, and four other top medtech experts regarding the agency’s upcoming harmonized QSR topped our list of most-read Medtech Insight articles in August.
The prefilled saline syringes were recalled because they could “reintroduce air into the syringe after the air has been expelled,” the manufacturer explains. The US FDA on 23 August affixed its highest risk classification, class I, to the recall.
The Safety Scalpel N11 is a component of Cardinal Health’s Argyle UVC Insertion Tray, which was recalled because it didn’t include the scalpel’s instructions for use. The recall has been labeled high-risk class I by the US FDA.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- The Harvard Drug Group
- VIASYS Healthcare